drugset / Trial / NCT01392989
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
NaSingle-groupOpen-labelTreatment
Summary
Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a treatment option for patients with myelodysplasia or myeloproliferative Disorders. During the course of this study, it will be evaluated whether a particular type of blood cell, called a cytokine-induced killer (CIK) cell, may add benefit to allogeneic stem cell transplantation. CIK cells are present in small quantities in the bloodstream but their numbers can be expanded after a brief period of nurturing in a laboratory.
Timeline
- Start
- 2011-03
- Primary completion
- 2016-06-07
- Completion
- 2017-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CIK cells | Cell therapy | 1e+08 cells/kg | — |
| Background | Cyclosporine | Peptide | 5 mg/kg | Oral |
| Background | Mycophenolate Mofetil | Small molecule | 15 mg/kg | Oral |
| Background | Thymoglobulin | Protein / enzyme biologic | 7.5 mg/kg | Intravenous |